Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17931 (
galectin-3
)
2,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous findings suggested that lower cell proliferation of clear cell carcinoma (CCC) of the ovary may contribute to its resistance to chemotherapy. We conducted the present study to find the gene that regulates cell proliferation of CCC and to elucidate whether it contributes to cisplatin (CDDP) resistance. Complementary DNA microarray analysis revealed that the gene expression level of
galectin-3
of CCC cell lines (KK, RMG-I,
HAC-2
) was over threefold higher than that of ovarian serous adenocarcinoma (SAC) cell lines (HRA, KF). S-phase fraction increased after knocking down
galectin-3
using small interfering RNA in RMG-I, KK, and
HAC-2
cells. The protein expression of p27 decreased after knocking down
galectin-3
. CDDP-induced apoptosis was increased after knocking down
galectin-3
, and this cytotoxic effect was canceled by roscovitine. Immunohistochemical staining showed that
galectin-3
expression in tumors of 20 CCC was significantly more frequent than that of 20 SAC (70.0% vs 15.0%, P = 0.0004). The present study showed that the expression of
galectin-3
in CCC might contribute to its lower cell proliferation and lead to CDDP resistance.
...
PMID:Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. 1743 67
